Rutz Michael P sold $2.8M of SHC

Rutz Michael P (President of Sterigenics) sold 150,000 shares of Sotera Health Co (SHC) at $18.84 ($2.83M total) on 2026-08-07.

Original reporting
SEC EDGAR · Rutz Michael P
Published Aug 11, 2026, 8:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 8:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SHC
Neutral
medium confidence
Mentioned
$SHC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SHCNeutralLow
01

Why it matters

A single insider open-market sale is typically a low-signal event for traders unless it is unusually large, part of coordinated selling, or accompanied by other negative disclosures. Here, the text provides transaction details but no fundamental update.

02

Market read

Traders may note the disclosed sale for sentiment monitoring, but there is no new operational or financial catalyst in the text.

03

What to watch

The article does not state whether other insiders sold/bought, whether the sale was part of a broader pattern, or whether there is any concurrent company-specific news.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-11 after-hours; sale executed 2026-08-07

Background

The article is an SEC Form 4 insider transaction disclosure for Sotera Health Co (SHC).

Company-level read

Ticker impact

$SHCNeutralMedium confidence
Context

Sotera Health insider Form 4 shows President of Sterigenics Michael P. Rutz sold 150,000 shares on 2026-08-07 for about $2.83M.

Expected impact

Low near-term impact; any reaction is likely limited to sentiment and should fade unless follow-on selling or new company news emerges.

Evidence & confidence

The filing is a disclosed transaction size of $2.83M, but the article provides no accompanying earnings, guidance, legal, or operational catalyst. Insider sales are common and often non-informational, though the absence of a stated 10b5-1 plan can add marginal uncertainty.

Market effects

Sterigenics-related insider activity may be watched by investors, but this filing alone does not signal sector-wide change.

None indicated.

None indicated.

Counterpoint

The sale could be driven by diversification or personal liquidity needs rather than negative expectations, so it may be over-interpreted.

Key entities

  • Sotera Health Co

    Company subject of the Form 4 insider transaction disclosure.

  • Michael P. Rutz

    President of Sterigenics and reporting officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

MedAI 8/10

Sotera Health Company Q3 2026 Earnings Call Summary

Sotera Health reported Q3 2026 earnings, with Sterigenics and Nelson Labs driving performance. Nordion saw revenue decline due to cobalt-60 timing. Management noted European market softness. Guidance reaffirmed, with flat Q4 Sterigenics revenue and reduced 2027 CapEx. Nelson Labs' growth expected to moderate. Net leverage improved to 2.9x, leading to a credit rating upgrade. Litigation and FX headwinds noted.

$SHCHighAI 8/10

Sotera Health (SHC) Q3 2026 Earnings Call Transcript

Sotera Health (SHC) reported Q3 2026 revenue growth of 4.4% to $325M and adjusted EBITDA growth of 4% to $171M. Sterigenics grew 8.2%, Nelson Labs 9.2%, and Nordion declined 11.5%. The company reaffirmed its 2026 revenue and adjusted EBITDA outlook, expecting 5.25-6.75% and 5.75-7.25% growth, respectively. Adjusted EBITDA margins expanded sequentially by 100 basis points to 52.5%.

$SHCHighAI 8/10

Why is Sotera Health stock sliding today?

Sotera Health (SHC) shares fell 9.5% despite Q3 2026 earnings beat (EPS $0.29, revenue $324.9M) due to cautious guidance. Revenue declined 12% in the Nordion segment. JPMorgan downgraded to Underweight with a $17 target, and insiders sold 1.29M shares. The S&P 500 and Nasdaq rose, but Sotera's decline was company-specific.

$SHCMed

What Sotera Health (SHC) Said on Its Q3 Earnings Call

Sotera Health (SHC) reported Q3 earnings, noting softness in the European medical-device market. Sterigenics expects 6% constant-currency growth in Q4, while Nelson Labs saw 8.8% revenue growth. Nordion revenue fell 12.4% due to shipment timing. The company reaffirmed its 2026 outlook for 5.25% to 6.75% revenue growth and maintained its adjusted EBITDA forecast.